Press Cutting



Client: Chi Med

Publication: The Guardian

Date: 6 November 2009



Hutchison China MediTech climbed 16p to 186.5p after successful phase 2B trials of its HMPL-004 ulcerative colitis drug. It will now find a major pharmaceutical firm to take the drug through phase 3 trials and then into production.

nick.fletcher@guardian.co.uk